JP2004532273A - 限局性の(localized)脂肪症(adiposity)およびセルライト(cellulite)の治療のための医薬用および/または化粧品用組成物 - Google Patents
限局性の(localized)脂肪症(adiposity)およびセルライト(cellulite)の治療のための医薬用および/または化粧品用組成物 Download PDFInfo
- Publication number
- JP2004532273A JP2004532273A JP2003501475A JP2003501475A JP2004532273A JP 2004532273 A JP2004532273 A JP 2004532273A JP 2003501475 A JP2003501475 A JP 2003501475A JP 2003501475 A JP2003501475 A JP 2003501475A JP 2004532273 A JP2004532273 A JP 2004532273A
- Authority
- JP
- Japan
- Prior art keywords
- complex
- phospholipid
- extract
- escin
- coleus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 239000002537 cosmetic Substances 0.000 title claims abstract description 11
- 208000035484 Cellulite Diseases 0.000 title claims description 12
- 206010049752 Peau d'orange Diseases 0.000 title claims description 12
- 230000036232 cellulite Effects 0.000 title claims description 12
- 208000023184 Body fat disease Diseases 0.000 title claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 14
- 235000021508 Coleus Nutrition 0.000 claims abstract description 13
- 244000061182 Coleus blumei Species 0.000 claims abstract description 13
- 229940011399 escin Drugs 0.000 claims abstract description 13
- 229930186222 escin Natural products 0.000 claims abstract description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 11
- 229930003935 flavonoid Natural products 0.000 claims abstract description 11
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 11
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 11
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 9
- 229940076810 beta sitosterol Drugs 0.000 claims abstract description 9
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims abstract description 9
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229950005143 sitosterol Drugs 0.000 claims abstract description 9
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims abstract description 9
- 150000003648 triterpenes Chemical class 0.000 claims abstract description 9
- 244000146462 Centella asiatica Species 0.000 claims abstract description 3
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 3
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 12
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 6
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 6
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 6
- 239000000539 dimer Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 description 9
- 230000007863 steatosis Effects 0.000 description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000003501 anti-edematous effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 241000157282 Aesculus Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000781615 Olax dissitiflora Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010036155 Poor peripheral circulation Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 235000006803 Ximenia Nutrition 0.000 description 1
- 241000488894 Ximenia Species 0.000 description 1
- VENIIVIRETXKSV-BQYQJAHWSA-N Ximenynic acid Chemical compound CCCCCC\C=C\C#CCCCCCCCC(O)=O VENIIVIRETXKSV-BQYQJAHWSA-N 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940098366 cola extract Drugs 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Abstract
Description
【0001】
本発明は、限局性の(localized)脂肪症(adiposity)およびセルライト(cellulite)の治療のための医薬用および/または化粧品用組成物に関する。
【背景技術】
【0002】
限局性の脂肪症およびセルライトは、顕著な、増加しているパーセントで、西部地区住民(western population)、おもに婦人を冒している(affect)。特に、セルライトは、多くの普通の体重を有する人々(normal weight-constitution)、肥満の(obesity)問題を抱えていない成人の婦人に感染している。これらの問題は、貧末梢循環(poor peripheral circulation)、浮腫(edema)、線維症(fibrosis)および変質した脂肪細胞代謝(altered lipocytes metabolism)によって特徴づけられる皮下脂肪層の(panniculopathy)病変(conditions)につながり、それゆえ理想の治療はこれらの要因を考慮する必要がある。
【0003】
大部分の現に市場で入手可能な限局性の脂肪症およびセルライトの治療のための医薬あるいは化粧品は、今のところ限局性の脂肪症およびセルライトの問題を満足に解決していない。該組成物は、一般に、例えばアイビー(ivy)、セイヨウトチノキ(horse-chestnut)、コーラ抽出物、カフェイン、β−アドレナリン性の刺激剤(beta-adrenergic stimulant)、メチルキサンチン等の植物起源の活性主成分に基づいている。しかしながら、今のところ該組成物のいずれもが実際に有効ではなく、得られた結論はしばしばかかる治療に関連する食事療法(dietetic regimen)の方が該組成物の使用よりはむしろ当然であるとされている。
【発明の開示】
【課題を解決するための手段】
【0004】
植物起源の活性主成分の組合せからなる医薬用および/または化粧品用局所用組成物が、限局性の脂肪症およびセルライトの治療に優れた結果を提供し、そして抗浮腫(anti-edematous)、抗ホスホジエステラーゼ、血管運動(vasokinetic)を働かせ、コラーゲン産生を増進する、種々の成分の異なる活性の組合せに基き、皮膚の(cutaneous)脂肪蓄積および“橙皮(orange-peel)”肌を劇的に軽減することが見出され、そしてこれが本発明の対象である。
【0005】
本発明の組成物の成分はすべて医薬分野においておよび/または化粧品分野において公知であり、用いられているが、該単独での成分の活性は、それらが別々に用いられたときには、本発明の組成物が達成している活性と比べはるかに低い;それに反して、これらの種々の成分間には共働効果(synergistic effect)が見られる。
【0006】
詳しくは、本発明は、活性主成分として、エスシン(escin)/β−シトステロールのリン脂質との複合体、ギンコビロバ(Gingko biloba)二量体フラボノイドのリン脂質との複合体、キシメニン酸エチル(ethyl ximeninate)、コレウスフォルスコリ(Coleus forskolii)エクストラクトおよびツボクサ(Centella asiatica)トリテルペンのリン脂質との複合体を含む医薬用および/または化粧品用局所用組成物を提供する。
【0007】
さらに詳しくは、本発明は、下記の活性主成分の組合わせを含む医薬用および/または化粧品用組成物である:
a)エスシン/β−シトステロールのリン脂質との複合体、
b)ギンコビロバ二量体フラボノイドのリン脂質との複合体、
c)ツボクサトリテルペンのリン脂質との複合体、
および任意に下記の一つまたは両方:
d)キシメニン酸エチル、
e)標準化コレウスフォルスコリエクストラクト。
【0008】
本発明の好ましい具体例としては、本発明の組成物は下記のパーセンテージの組成をしている:
a)エスシン/β−シトステロールのリン脂質との複合体:0.1〜2.5%;
b)ギンコビロバ二量体フラボノイドのリン脂質との複合体:0.1〜2.5%;
c)ツボクサトリテルペンのリン脂質との複合体:0.1〜2.5%、
および任意に下記の一つまたは両方:
d)キシメニン酸エチル:0.1〜2.5%;
e)コレウスフォルスコリ標準化エクストラクト:0.1〜2.5%。
【発明を実施するための最良の形態】
【0009】
エスシンはセイヨウトチノキの種に含まれる、多分毛細血管の透過性の修正により、顕著な抗浮腫性を与える、サポニンである:実際、エスシンは水交換を起こす毛細血管壁の細孔の数および直径を減らすことができることが証明されている。それゆえ、エスシンの性質は、セルライトおよび限局性の脂肪症を代表する限局性の浮腫状態の治療に有用であると考えられる。
【0010】
ヨーロッパ特許0283713に開示されている、エスシン/β−シトステロールのリン脂質との複合体は、エスシンと同様の活性を有するが、活性主成分のより引き伸ばされた放出と改善された生物学的利用能が観測される。
【0011】
ヨーロッパ特許0275005に開示されている、ギンコビルバ二量化フラボノイドのリン脂質との複合体は、遊離状態にある二量化ギンコビルバフラボノイドと同様の活性を有するが、活性主成分のより引き伸ばされた放出とより良い生物学的利用能が観測される。ギンコビルバ二量化フラボノイドは肥満細胞(mast cell)からのヒスタミンのおよび酵素cAMPホスホジエステラーゼの分泌への抑制的作用に基き血管活性化剤として特に効能がある。この酵素の抑制はcAMP(脂肪細胞の代謝を活性化することができる分子)のレベルの増加を伴う。それゆえ、この複合体は脂肪分解の活性を働かせ、微小血管の灌流(perfusion)および皮膚の栄養(trophism)を改善する。
【0012】
ツボクサトリテルペン(アシアチック酸(asiatic acid)、アシアチコシド(asiaticoside)およびマデカシック酸(madecassic acid))は、ヒドロキシプロリン(コラーゲ合成の基本物質である)の吸収を増加させることにより、真皮の線維芽細胞によるコラーゲン(安定型で)の産生に有利な活性を及ぼし、それよってセルライトの代表である“橙皮肌”形成に対し作用して皮膚の硬化(sclerosis)を対比する。ヨーロッパ特許0283713に開示されたツボクサトリテルペンのリン脂質との複合体は引き伸ばされた放出と真皮へのよりよい浸透性を示す。
【0013】
キシメニン酸エチルは、キシメニン酸(オラックスジシチフロラ(Olax dissitiflora)およびボロボロノキ科(Ximenia)の油気のある植物に見出される脂肪酸)のエチルエステルである。進歩したキャピラロスコピック(capillaroscopic)技法はキシメニン酸エチルが重要な血管運動活性を持つことを示した。これは、剤の他の活性主成分の活性と組み合わさって、セルライトの治療に有用である。
【0014】
標準化コレウスフォルスコリエクストラクト(実施例1に記載した)はフォルスコリン(アデニレートシクラーゼ(adenylate cyclase)活性を刺激し、それにより環状ニュクレオチド(微小血管レベルでの脂肪分解および血液流を活性化する分子)の濃度を増加させることができる良い特徴を持つ分子)を含む。
【0015】
本発明の組成物は、限局性の脂肪症および/またはセルライトの起きた身体部署に、治療される病気(disorder)の激しさ(severity)に応じて、数日から数ヶ月間、日に1−2回の塗布頻度で、局所的に(topically)塗布される。
【0016】
本発明の組成物は、通常の技法に従って、クリーム、オイル、ジェル、あわ、乳液、ミルク等の形で、任意にリポゾーム中にカプセル化されて、製造される。該組成物は医薬および/または化粧品技術で通常に用いられる賦形剤を含む。
【実施例】
【0017】
以下に製剤の例が示される。
【0018】
実施例1 コレウスフォルスコリの20%フォルスコリン標準化エクストラクトの製造
よく粉砕されたコレウスフォルスコリの根茎(rhizome)および根1kgが、続いて連続循環の下にCO210リットルで、45℃、240バール(240×105Pa)で2時間抽出される。50℃での溶媒の蒸発後、残渣は5容量倍のヘキサンに溶解され、2容量倍の90%v/vのメタノールで2回逆抽出される。
【0019】
メタノール抽出液は乾固するまで濃縮され、20%のフォルスコリンを含むエクストラクト45gが得られる。
【0020】
実施例2 クリーム剤
クリーム100gは以下を含む。
エスシン/Β−シトステロールのリン脂質との複合体 1.50g
ツボクサトリテルペンのリン脂質との複合体 0.50g
二量化ギンコビロバフラボノイドのリン脂質との複合体 0.50g
コレウスフォルスコリ標準化エクストラクト(20%フォルスコリン) 0.50g
キシメニン酸エチル 0.50g
安息香酸C12−C15アルキル(Finsolv TN−Fintex社製) 7.50g
シクロメチコン(Belsil CMO40−Wacker社製) 6.00g
エトキシジグリコール(Transcutol CG−Gattefosse社製) 5.00g
ステアリン酸グリセリルとステアリン酸PEG−100 3.00g
(Arlacel 165V−ICI社製)
カリテ(Karite)バター(シアバター(Shea butter)) 3.00g
(Dekarite−Jan Dekker社製)
ポリソルベート60(Tween 60−ICI社製) 2.00g
セチルアルコール 1.00g
アボカド油(Avocado oil−Jan Dekker社製) 1.00g
酢酸ビタミンE 0.20g
パルミチン酸アスコルビル 0.10g
ポリアクリルアミドとC13−14イソパラフィンとラウレス−7 3.00g
(Sepigel 305−Seppic社製)
イミダゾーリヂニルウレア 0.30g
メチルクロロイソチアゾリノンとメチルイソチアゾリノン 0.05g
(Kathon CG−Rohm&Haas社製)
EDTA二ナトリウム 0.10g
BHT 0.05g
香料(162−AGF社製) 0.20g
浄化された水 100gに満ちるまで
Claims (5)
- 下記成分を含む医薬用および/または化粧品用組成物:
a)エスシン(escin)/β−シトステロールのリン脂質との複合体、
b)ギンコビロバ(Gingko biloba)二量体フラボノイドのリン脂質との複合体、
c)ツボクサ(Centella asiatica)トリテルペンのリン脂質との複合体、
および任意に下記の一つまたは両方:
d)キシメニン酸エチル(ethyl ximeninate)、
e)コレウスフォルスコリ(Coleus forskolii)エクストラクト。 - 下記のパーセンテージ組成を有する、請求項1に記載の組成物:
a)エスシン/β−シトステロールのリン脂質との複合体:0.1〜2.5%;
b)ギンコビロバ二量体フラボノイドのリン脂質との複合体:0.1〜2.5%;
c)ツボクサトリテルペンのリン脂質との複合体:0.1〜2.5%;
および任意に下記の一つまたは両方:
d)キシメニン酸エチル:0.1〜2.5%;
e)コレウスフォルスコリエクストラクト:0.1〜2.5%。 - 下記を含む、請求項1または2に記載の組成物:
a)エスシン/β−シトステロールのリン脂質との複合体 1.50g、
b)ツボクサトリテルペンのリン脂質との複合体 0.50g、
c)ギンコビロバ二量体フラボノイドのリン脂質との複合体 0.50g、
d)コレウスフォルスコリ標準化エクストラクト(20%フォルスコリン(forskolin))
0.50g、
e)キシメニン酸エチル 0.50g。 - コレウスフォルスコリエクストラクトが20%フォルスコリン標準化エクストラクトであることを特徴とする請求項1または2に記載の組成物。
- 請求項1〜4のいずれか1項に記載の組成物を治療される領域に塗布することを含む、限局性の(localized)脂肪症(adiposity)および/またはセルライト(cellulite)の化粧的治療法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001MI001182A ITMI20011182A1 (it) | 2001-06-05 | 2001-06-05 | Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite |
ITMI01A001182 | 2001-06-05 | ||
PCT/EP2002/005390 WO2002098436A1 (en) | 2001-06-05 | 2002-05-16 | Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004532273A true JP2004532273A (ja) | 2004-10-21 |
JP4762492B2 JP4762492B2 (ja) | 2011-08-31 |
Family
ID=11447807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003501475A Expired - Fee Related JP4762492B2 (ja) | 2001-06-05 | 2002-05-16 | 化粧品用組成物 |
Country Status (23)
Country | Link |
---|---|
US (1) | US7476392B2 (ja) |
EP (1) | EP1392335B1 (ja) |
JP (1) | JP4762492B2 (ja) |
KR (1) | KR100869868B1 (ja) |
CN (1) | CN100340247C (ja) |
AT (1) | ATE360427T1 (ja) |
AU (1) | AU2002304632B2 (ja) |
CA (1) | CA2449485C (ja) |
CY (1) | CY1107672T1 (ja) |
CZ (1) | CZ300576B6 (ja) |
DE (1) | DE60219782T2 (ja) |
DK (1) | DK1392335T3 (ja) |
ES (1) | ES2284870T3 (ja) |
HK (1) | HK1063295A1 (ja) |
HU (1) | HU230348B1 (ja) |
IT (1) | ITMI20011182A1 (ja) |
NO (1) | NO331789B1 (ja) |
PL (1) | PL204550B1 (ja) |
PT (1) | PT1392335E (ja) |
RU (1) | RU2291683C2 (ja) |
SI (1) | SI1392335T1 (ja) |
SK (1) | SK287612B6 (ja) |
WO (1) | WO2002098436A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009513518A (ja) * | 2003-07-11 | 2009-04-02 | インデナ エッセ ピ ア | 血管作用物質の組合せおよび性機能不全の治療におけるそれらの使用 |
JP2009513519A (ja) * | 2003-07-11 | 2009-04-02 | インデナ エッセ ピ ア | 血管作用剤の組合せ物、それらの薬剤および化粧品分野での使用、ならびにそれらを含む製剤 |
KR20120103758A (ko) * | 2009-08-12 | 2012-09-19 | 호르파그 리서치 아이피 (피와이씨) 리미티드 | 동맥경화증과 같은 심혈관 장애의 치료용 피크노제놀 또는 포도씨와 같은 프로안토시아니딘 및 병풀의 조합 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20021280A1 (it) * | 2002-06-11 | 2003-12-11 | Carlo Ghisalberti | Metodo di trattamento anticellulite |
FR2841470B1 (fr) * | 2002-06-27 | 2006-01-13 | Pharmascience Lab | Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee |
DE10349979B4 (de) * | 2003-10-24 | 2006-05-18 | Sanofi-Aventis Deutschland Gmbh | Medikamentöse gezielte lokale Lipolyse |
US20050089555A1 (en) * | 2003-10-24 | 2005-04-28 | Aventis Pharma Deutschland Gmbh | Medicinal targeted local lipolysis |
US20050143347A1 (en) * | 2003-12-22 | 2005-06-30 | Aventis Pharma Deutschland Gmbh | Medicinal lipolysis of accumulations of fat |
NZ555836A (en) * | 2004-12-14 | 2009-09-25 | Menarini Ricerche Spa | Pharmaceutical compositions for the treatment of cellulite |
EP1849481A4 (en) * | 2005-01-07 | 2012-11-28 | Rohto Pharma | COMPOSITION FOR TOPICAL APPLICATION |
DE102005061071A1 (de) * | 2005-12-21 | 2007-06-28 | Kneipp-Werke Kneipp-Mittel-Zentrale Gmbh & Co. Kg | Wirkstoffkombination aus Santalbinsäure oder Derivate davon und Traubenkernöl zur topischen oder dermatologischen Verwendung |
DE102007007610A1 (de) * | 2007-02-13 | 2008-08-14 | Beiersdorf Ag | Verfahren zur Steigerung der Hautelastizität und/oder eine Stärkung der Spannkraft der Haut |
ITTO20070391A1 (it) * | 2007-06-05 | 2008-12-06 | Medestea Res & Production S P | Composizione di integratore alimentare,farmaco o dispositivo medicale e suo impiego per sopprimere l'appetito, migliorare tono ed umore, con attivita antidepressiva naturale e con effetto antiastenico |
EP2419437A1 (en) * | 2009-04-17 | 2012-02-22 | Lipotec, S.A. | Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions |
DE102009028996A1 (de) * | 2009-08-28 | 2011-03-03 | Rovi Cosmetics International Gmbh | Kosmetische Formulierung zur Reduktion der äußeren Erscheinungsbilder von Cellulite oder Orangenhaut |
FR2962907B1 (fr) * | 2010-07-21 | 2015-05-08 | Ephyla Sas | Extrait de vegetal pour la fabrication de composition amincissante et procede de controle pour mincir mettant en oeuvre une telle composition |
BE1022293B1 (nl) | 2012-11-21 | 2016-03-14 | Wendy Angrave | Methode en composities om toxines te verwijderen uit het lichaam |
CA2905756C (en) | 2013-03-15 | 2016-11-29 | Mary Kay Inc. | Cosmetic compositions for reducing the appearance of cellulite or improving skin texture |
CN103432045B (zh) * | 2013-09-06 | 2015-06-24 | 雅露拜尔生物科技(杭州)有限公司 | 健美瘦身组合物及健美瘦身霜 |
WO2022178967A1 (zh) * | 2021-02-24 | 2022-09-01 | 中国药科大学 | 佛司可林-异佛司可林与五环三萜类化合物的药物组合物及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1203515B (it) * | 1987-02-26 | 1989-02-15 | Indena Spa | Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono |
IT1223290B (it) * | 1987-07-27 | 1990-09-19 | Indena Spa | Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche |
FR2669537B1 (fr) * | 1990-11-28 | 1993-02-19 | Oreal | Composition amincissante a base d'alpha-2-bloqueurs. |
FR2684300B1 (fr) * | 1991-11-29 | 1994-03-11 | Lvmh Recherche | Composition cosmetique ou pharmaceutique, notamment dermatologique, destinee en particulier a favoriser la pigmentation de la peau ou des cheveux, contenant un extrait de ballote, et son procede de fabrication. |
JPH10182473A (ja) * | 1996-12-25 | 1998-07-07 | Lion Corp | 皮下脂肪代謝促進剤及びそれを含む外用組成物 |
EP1214084B1 (en) * | 1999-09-10 | 2005-04-06 | Ceteris Holding B.V.-Amsterdam (Olanda) - Succursale di Lugano | An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems |
-
2001
- 2001-06-05 IT IT2001MI001182A patent/ITMI20011182A1/it unknown
-
2002
- 2002-05-16 DE DE60219782T patent/DE60219782T2/de not_active Expired - Lifetime
- 2002-05-16 CA CA2449485A patent/CA2449485C/en not_active Expired - Fee Related
- 2002-05-16 SK SK1485-2003A patent/SK287612B6/sk not_active IP Right Cessation
- 2002-05-16 PT PT02732718T patent/PT1392335E/pt unknown
- 2002-05-16 AU AU2002304632A patent/AU2002304632B2/en not_active Ceased
- 2002-05-16 CN CNB028112911A patent/CN100340247C/zh not_active Expired - Fee Related
- 2002-05-16 ES ES02732718T patent/ES2284870T3/es not_active Expired - Lifetime
- 2002-05-16 KR KR1020037015485A patent/KR100869868B1/ko not_active IP Right Cessation
- 2002-05-16 CZ CZ20033293A patent/CZ300576B6/cs not_active IP Right Cessation
- 2002-05-16 EP EP02732718A patent/EP1392335B1/en not_active Expired - Lifetime
- 2002-05-16 PL PL366914A patent/PL204550B1/pl unknown
- 2002-05-16 WO PCT/EP2002/005390 patent/WO2002098436A1/en active IP Right Grant
- 2002-05-16 HU HU0400119A patent/HU230348B1/hu not_active IP Right Cessation
- 2002-05-16 JP JP2003501475A patent/JP4762492B2/ja not_active Expired - Fee Related
- 2002-05-16 SI SI200230545T patent/SI1392335T1/sl unknown
- 2002-05-16 AT AT02732718T patent/ATE360427T1/de active
- 2002-05-16 US US10/477,923 patent/US7476392B2/en not_active Expired - Lifetime
- 2002-05-16 RU RU2003135427/15A patent/RU2291683C2/ru not_active IP Right Cessation
- 2002-05-16 DK DK02732718T patent/DK1392335T3/da active
-
2003
- 2003-12-04 NO NO20035389A patent/NO331789B1/no not_active IP Right Cessation
-
2004
- 2004-08-13 HK HK04106092A patent/HK1063295A1/xx not_active IP Right Cessation
-
2007
- 2007-06-14 CY CY20071100788T patent/CY1107672T1/el unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009513518A (ja) * | 2003-07-11 | 2009-04-02 | インデナ エッセ ピ ア | 血管作用物質の組合せおよび性機能不全の治療におけるそれらの使用 |
JP2009513519A (ja) * | 2003-07-11 | 2009-04-02 | インデナ エッセ ピ ア | 血管作用剤の組合せ物、それらの薬剤および化粧品分野での使用、ならびにそれらを含む製剤 |
JP4892342B2 (ja) * | 2003-07-11 | 2012-03-07 | インデナ エッセ ピ ア | 血管作用物質の組合せおよび性機能不全の治療におけるそれらの使用 |
KR20120103758A (ko) * | 2009-08-12 | 2012-09-19 | 호르파그 리서치 아이피 (피와이씨) 리미티드 | 동맥경화증과 같은 심혈관 장애의 치료용 피크노제놀 또는 포도씨와 같은 프로안토시아니딘 및 병풀의 조합 |
JP2013501774A (ja) * | 2009-08-12 | 2013-01-17 | ホーファグ リサーチ アイピー (ピーワイシー) リミテッド | アテローム性動脈硬化症などの心血管障害の処置のためのピクノジェノールまたはブドウ種子などのプロアントシアニジンとCentellaasiaticaとの組み合わせ |
KR101678254B1 (ko) | 2009-08-12 | 2016-11-21 | 호르파그 리서치 아이피 (피와이씨) 리미티드 | 동맥경화증과 같은 심혈관 장애의 치료용 피크노제놀 또는 포도씨와 같은 프로안토시아니딘 및 병풀의 조합 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4762492B2 (ja) | 化粧品用組成物 | |
KR101527829B1 (ko) | 마그놀리아 추출물 함유 조성물 | |
US10226495B2 (en) | Hair loss compositions and methods of making and using same | |
EP1002526B1 (en) | Skin whitening composition containing bearberry extract and a reducing agent | |
JP3091782B2 (ja) | 化粧料用痩身剤組成物 | |
AU2002304632A1 (en) | Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite | |
CA2294062A1 (en) | Isoflavonoids for treatment and prevention of aging skin and wrinkles | |
EP1648403B1 (en) | Slimming cosmetic composition comprising cafestol or kahweol | |
FR2671487A1 (fr) | Utilisation d'un facteur de croissance dans une composition amincissante. | |
US9149665B2 (en) | Method and composition for reducing appearance of wrinkles | |
CA2467734A1 (fr) | Composition a base d'ester de diosgenine applicable par voie topique. | |
JP2004256485A (ja) | 皮膚外用剤 | |
CN111840150A (zh) | 淡斑祛痘护肤粉 | |
JPH10182473A (ja) | 皮下脂肪代謝促進剤及びそれを含む外用組成物 | |
KR100444102B1 (ko) | 백자인 추출물 함유 발모촉진용 화장료 조성물 | |
JP3553179B2 (ja) | 美白剤 | |
EP1566169A1 (en) | Cosmetic compositions containing combinations of Bupleurum species extracts and Salvia miltiorrhiza extracts for the treatment and reduction of blemishes caused by cellulite | |
FR2876912A1 (fr) | Nouvelle utilisation de guggulipides en therapeutique et en cosmetique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050413 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20051208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060314 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070717 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20071001 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20071001 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20071102 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080229 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110125 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110221 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110322 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110608 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140617 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |